Literature DB >> 27914940

Soluble urokinase-type plasminogen activator receptor (suPAR) in patients with acute pancreatitis (AP) - Progress in prediction of AP severity.

Michal Lipinski1, Alicja Rydzewska-Rosolowska2, Andrzej Rydzewski3, Malgorzata Cicha4, Grazyna Rydzewska5.   

Abstract

BACKGROUND: Soluble urokinase-type plasminogen activator receptor (suPAR) is a glycoprotein secreted during inflammation and infections. Moreover, increased levels of suPAR are observed after hypoxia and ischaemia. The aim of the study was to assess whether suPAR could represent a useful marker of acute pancreatitis (AP) severity. PATIENTS AND METHODS: We have observed a cohort of 126 prospectively enrolled patients. Based on the presence of persistent organ failure (more than 48 h) and local complications (diagnosis of moderate AP [MSAP]), patients were classified into three groups: mild AP (MAP), moderate and severe AP (SAP). The blood samples were taken on admission for detecting suPAR concentrations.
RESULTS: AP was considered severe in 33 patients (26.2%), MSAP was found in 37 patients (29.4%), and MAP was found in 56 patients (44,4%). The AUC for SAP predicted by suPAR was 0.993. The calculated cut-off point for prognosis SAP is 4.75 ng/mL. The BISAP score of ≥3 for detection of SAP had sensitivity and specificity of 94.6% and 63.6%, respectively. The AUC for severity predicted by BISAP amounted to 0.916. Additionally, suPAR turned out to be a good predictor of fatal AP: for the cut-off point 7.05 ng/mL, the AUC was 0.917. The AUC for death prediction in AP patients based on the BISAP score ≥3 was 0.894.
CONCLUSIONS: suPAR concentration is a promising new diagnostic and prognostic indicator in SAP obtainable in the early stage of disease. Larger studies are recommended to evaluate this role further.
Copyright © 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acute pancreatitis; Mortality; Prediction; suPAR

Mesh:

Substances:

Year:  2016        PMID: 27914940     DOI: 10.1016/j.pan.2016.11.005

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  6 in total

1.  Acute pancreatitis and the weekend effect: does weekend admission affect patient outcome?

Authors:  Michał Lipiński; Grażyna Rydzewska
Journal:  Prz Gastroenterol       Date:  2020-09-19

2.  Immature granulocytes predict severe acute pancreatitis independently of systemic inflammatory response syndrome.

Authors:  Michał Lipiński; Grażyna Rydzewska
Journal:  Prz Gastroenterol       Date:  2017-06-13

3.  Serum Urokinase-Type Plasminogen Activator Receptor Does Not Outperform C-Reactive Protein and Procalcitonin as an Early Marker of Severity of Acute Pancreatitis.

Authors:  Witold Kolber; Beata Kuśnierz-Cabala; Paulina Dumnicka; Małgorzata Maraj; Małgorzata Mazur-Laskowska; Michał Pędziwiatr; Piotr Ceranowicz
Journal:  J Clin Med       Date:  2018-09-27       Impact factor: 4.241

4.  Leukocyte cell population data from the blood cell analyzer as a predictive marker for severity of acute pancreatitis.

Authors:  Yihui Wang; Zhihong Xu; Yuhua Zhou; Mengqi Xie; Xing Qi; Zhiwei Xu; Qi Cai; Huiqiu Sheng; Erzhen Chen; Bing Zhao; Enqiang Mao
Journal:  J Clin Lab Anal       Date:  2021-06-01       Impact factor: 2.352

5.  Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study.

Authors:  Line J H Rasmussen; Steen Ladelund; Thomas H Haupt; Gertrude E Ellekilde; Jesper Eugen-Olsen; Ove Andersen
Journal:  Crit Care Med       Date:  2018-12       Impact factor: 7.598

6.  Assessment of the course of acute pancreatitis in the light of aetiology: a systematic review and meta-analysis.

Authors:  Emese Réka Bálint; Gabriella Fűr; Lóránd Kiss; Dávid István Németh; Alexandra Soós; Péter Hegyi; Zsolt Szakács; Benedek Tinusz; Péter Varjú; Áron Vincze; Bálint Erőss; József Czimmer; Zoltán Szepes; Gábor Varga; Zoltán Rakonczay
Journal:  Sci Rep       Date:  2020-10-21       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.